Clinical trial · Interventional
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NPC)
NCT00436800CI-TRIAL-00002644completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary objective: To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma. Secondary objectives: To assess the toxicity, duration of response, time to progression, progression-free survival, overall survival and cancer-related symptoms in the first line treatment of patients with metastatic or recurrent NPC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Neoplasms | Nasopharyngeal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Gemcitabine on Day 1 followed by Oxaliplatin on Day 2. The regimen is given every 2 weeks to a maximum of 12 cycles.
- interventionNames
- Drug: Gemcitabine
- Drug: Oxaliplatin
Primary outcomes (5)
- measure
- Efficacy: Tumor response rate based on Response Evaluation Criteria in Solid Tumour (RECIST) criteria
- timeFrame
- Baseline to end of study
- measure
- Safety: Clinical and laboratory criteria
- timeFrame
- Baseline to end of study
- measure
- The incidence of adverse events based on National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically or cytologically proven nasopharyngeal carcinoma (NPC) with metastatic or recurrent disease that is not amenable to potentially curative surgery or radiotherapy. They must not have prior chemotherapy for the treatment of metastatic or recurrent disease. * Prior neoadjuvant, adjuvant or concurrent chemotherapy is allowed as long as a minimum period of 6 weeks has elapsed since the last day of treatment. This includes the use of carboplatin or cisplatin. * Patients must have at least one uni-dimensional measurable lesion (according to RECIST criteria) * Prior RT or surgery to the target lesion(s) is allowed as long as there is documented disease progression within the RT/ surgical field, and a minimum period of 6 weeks has elapsed since the last day of treatment. * Eastern Cooperative Oncology Group performance status of 0-2 * No serious, uncontrolled medical conditions that may be aggravated by treatment. * No other malignancy(s), except completely excised basal or squamous cell carcinoma of the skin, or completely treated carcinoma-in-situ of the cervix. * Adequate hematological function:absolute granulocyte count \> 1.5 x 10\^9/L, platelet count \> 100 x 10\^9/L * Adequate renal and hepatic functions:·serum creatinine \< 1.25 x upper normal limit (UNL) or a calculated creatinine clearance \> 50 mL/min·serum bilirubin \< 2 x UNL and Aspartate aminotransferase/Alanine aminotransferase \< 3 x UNL Exclusion Criteria: * Prior treatment with Oxaliplatin or Gemcitabine. * Patients who have persistent grade 2 or more sensory and/or motor neuropathy, or ototoxicity resulting from prior cisplatin/ carboplatin. * Active or past history of central nervous system metastasis from the primary tumor * Potentially life-threatening infections * Patients have used any investigational drug treatment in the month prior to inclusion. * Pregnancy or not exercising appropriate birth control during the course of the study. Breast-feeding women The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.